Document DoNn9E441ZBya8naw8j6vvdM

To: Russell White <whiter@api.org> From: michael. g. bi rd @exxonmobil.com <michael. g. bi rd @exxonmobil.com> Cc: Bruce Jarnot <jarnotb@api.org>; Cagen, Stuart Z SHLOIL-SHOIL-SHS <stuart. cagen@shell.com>; stephen. m. bowes@exxonmobil.com <stephen. m. bowes@exxonmobil.com> Bcc: Received Date: 2006-11-1320:59:54 GMT Subject: RE: Shanghai Health Study - new budget estimate Excellent, thanks for the confirmation. Michael Michael G. Bird, PhD., DABT Toxicology & Environmental Sciences Division, ExxonMobil Biomedical Sciences, Inc. 1545 Route 22 East P.O. Box 971 Annandale, New Jersey 08801-0971 tel: 9087301060 fax: 908 730 1199 Email: michael.g.bird@exxonmmobil.com This document and all information contained within this electronic message may be privileged, confidential and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited. "Russell White" <whiter@api.or To g> <michael.g.bird@exxonmobil.com> cc <stuart.cagen@shell.com>, "Bruce 11/13/0603:56 Jarnot" <jarnotb@api.org> PM Subject RE: Shanghai Health Study - new budget estimate API has a separate with Fudan for support of the case-control study. I'm putting together a spreadsheet that will include the new data and estimates for all contracts. -----Original Message----- SH ELL-MCCLU RG-064827 From: michael.g.bird@exxonmobil.com [mailto:michael.g.bird@exxonmobil.com] Sent: Monday, November 13, 2006 3:49 PM To: Russell White Cc: stuart.cagen@shell.com Subject: Re: Shanghai Health Study - new budget estimate Russ, I know that Stuart is working Otto Wong's needs, but I believe there was mention of some separate contract or support for Dr Fu? If so is that part of Otto's contract or a separate EA activity? Just want to make sure that everything is covered. Michael Michael G. Bird, PhD., DABT Toxicology & Environmental Sciences Division, ExxonMobil Biomedical Sciences, Inc. 1545 Route 22 East P.O. Box 971 Annandale, New Jersey 08801-0971 tel: 9087301060 fax: 908 730 1199 Email: michael.g.bird@exxonmmobil.com This document and all information contained within this electronic message may be privileged, confidential and exempt from disclosure under applicable law. It is intended only for the use of the individual(s) and/or entity(ies) named above. If you are not the intended recipient, you are on notice that any unauthorized disclosure, copying, distribution, or taking of any action in reliance on the contents of the electronically transmitted materials is prohibited. "Russell White" <whiter@api.or To g> <BenzConsort-OC@listserve.api.org>, <BenzConsort-TC@listserve.api.org> cc 11/13/0602:57 PM Subject Shanghai Health Study - new budget estimate SH ELL-MCCLU RG-064828 Greetings, Some OC members have asked for an estimate of individual company costs base on Dr. Irons new budget estimates. Using the eleven shares formula (XOM and BP have 3 shares, Chevron and Shell have 2 shares, and ConocoPhillips has 1 share); Finish study - $5,759,864 1 share $523,624 2 shares $1 ,047,248 3 shares $1 ,570,872 Finish study and transition lab - $6,999,864 1 share $636,351 2 shares $1 ,272,703 3 shares $1 ,909,054 Finish study, transition lab, and publish results - $7,599,864 1 share $690,897 2 shares $1 ,381 ,793 3 shares $2,072,690 SH ELL-MCCLU RG-064829